Plasmalogen Therapeutics

 

Med-Life Discoveries is a clinical-stage biopharma company developing novel plasmalogen-based therapeutics for the treatment of Rhizomelic Chondrodysplasia Punctata (RCDP) and other neurological conditions*

*MLD’s plasmalogen therapeutics are currently undergoing required formal regulatory safety and efficacy studies and are not currently available to the public.

News

Catch up on our latest whereabouts and milestones here!

Peroxisomal Disorders

Rhizomelic Chondrodysplasia Punctata (RCDP) affects fewer than 100 patients in North America. But there is #hopeforRCDP and other plasmalogen-deficient peroxisomal disorders with PPI-1011: a first-in-class plasmalogen therapy in clinical development.

 
 

Neurological Conditions

Plasmalogen deficiency is associated with several neurological conditions including Alzheimer’s disease, Parkinson’s disease, and Multiple sclerosis. Therapeutically augmenting plasmalogens represents a new paradigm for the management of these diseases.

 
 

Literature

Relevant literature, curated by our own scientific communications team